Utilization of data below the analytical limit of quantitation in pharmacokinetic analysis and modeling: promoting interdisciplinary debate by Hecht, M et al.
Utilization of data below the analytical limit of quantitation in pharmacokinetic analysis and 
modeling: promoting interdisciplinary debate 
Max Hecht1,2, Ruta Veigure1, Lewis Couchman2, Charlotte I S Barker3,4,5, Joseph F 
Standing3,4, Kalev Takkis2, Hanno Evard1, Atholl Johnston2,6, Koit Herodes1, Ivo Leito*,1 & 
Karin Kipper**,1,2 
 
1Chair of Analytical Chemistry, Institute of Chemistry, University of Tartu, 14a Ravila 
Street, 50411 Tartu, Estonia 
2Analytical Services International, St George’s University of London, Cranmer Terrace, 
London, SW17 0RE, UK 
3Paediatric Infectious Diseases Research Group, Institute for Infection & Immunity, St 
George’s University of London, London, 
SW17 0RE, UK 
4Inflammation, Infection & Rheumatology Section, UCL Great Ormond Street Institute of 
Child Health, London, WC1N 1EH, UK 
5Paediatric Infectious Diseases Unit, St George’s University Hospitals NHS Foundation 
Trust, London, SW17 0RE, UK 
6Clinical Pharmacology, Barts & The London School of Medicine & Dentistry, Queen Mary 
University of London, London, EC1M 
6BQ, UK 
*Authors for correspondence: ivo.leito@ut.ee 
**Authors for correspondence: karin.kipper@gmail.com 
 
  
Summary: 
Traditionally, bioanalytical laboratories do not report actual concentrations for samples with 
results below the limit of quantification (BLQ) in pharmacokinetic studies. BLQ values are outside 
the method calibration range established during validation and no data are available to support the 
reliability of these values. However, ignoring BLQ data can contribute to bias and imprecision in 
model-based pharmacokinetic analyses. From this perspective, routine use of BLQ data would be 
advantageous.  
We would like to initiate an interdisciplinary debate on this important topic by summarising the 
current concepts and use of BLQ data by regulators, pharmacometricians and bioanalysts. Through 
introducing the limit of detection and evaluating its variability BLQ data could be released and 
utilized appropriately for pharmacokinetic research. 
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Introduction 
Studying the effects of drugs remains central to both medical research and clinical practice. Two 
key branches of pharmacological analysis are (i) pharmacokinetics (PK), including drug 
absorption, distribution, metabolism and elimination, and (ii) pharmacodynamics (PD), exploring 
the effects of drugs on the living organism, including efficacy and toxicity. In PK studies the 
samples are collected in an effort to map the drug concentration over time in the patient. For 
samples collected many hours post-dose drug concentrations may be low, yet can still provide 
valuable information on pharmacokinetic parameters such as clearance [1,2]. Similarly, in the case 
of biomarker PD studies, concentrations that are too low to quantify with a particular bioanalytical 
method may still provide useful information. 
Bioanalytical laboratories define the lowest concentration that can be quantified accurately by a 
method as the lower limit of quantification (LLOQ). For chromatographic methods, the precision 
and accuracy of the LLOQ calibrator are determined experimentally during the method validation 
process. In practice, the assigned concentration of the LLOQ calibrator may arise from many 
sources, including pre-existing experimental data or literature references suggesting a 
concentration range for a drug in a particular matrix, or predicted drug concentrations based on 
dosing information. In addition, chromatographic methods have a limited linear dynamic range 
(i.e. a range across which the instrument response is linear with respect to concentration). If the 
assay is designed to include a high upper limit of quantitation (ULOQ) to quantify accurately 
samples at peak drug concentration (without having to dilute too many samples), and the linear 
range of the assay/instrument is limited, this may result in a high LLOQ concentration. 
For the LLOQ calibrator, the within-assay and between-assay coefficients of variation (CV, %) 
must be consistently (i.e. between-assay precision from at least three batch assays, with five 
replicates within each batch assay) less than or equal to 20 % [3–7]. For immunoassays, such as 
enzyme linked immunosorbent assays (ELISAs), larger CV values (25 % at LLOQ) are acceptable 
[3]. In study reports generated by bioanalytical laboratories, concentrations measured below the 
LLOQ are typically reported textually as ‘below the limit of quantification’ (BLQ) or similar, 
rather than as a numeric value.  
Since no precision and accuracy data are acquired during the method validation for concentrations 
below the LLOQ (BLQ), these data are considered invalid. The OECD Good Laboratory Practice 
(GLP) guidelines require that Study Directors ensure the quality and validity of the data handed 
out [8], which are simply unknown for data BLQ and therefore these data should not be released.   
Design of the bioanalytical assay should be well aligned with the concentrations expected in the 
clinical samples. A suitable concentration range and the LLOQ for the assay should be selected. 
This may be based on pre-existing data about expected drug concentrations in real samples (e.g. 
from existing literature, animal models in case of first-in-human studies, adult models for 
paediatric studies, or at worst, data about similar drugs and dosing regimens). The aim is to ensure 
the maximum number of samples fall within the assay concentration range. In well-designed 
clinical studies, the amount of BLQ data should be minimal.  
An example PK model is shown in Figure 1. The model is based on analysis of a drug using three 
different assays, each with a different LLOQ concentration, and different precision values at the 
LLOQ concentrations. The dashed line for each assay represents the LLOQ concentration, and the 
grey highlights show the experimentally determined between-day precision (CV, %) at the 
designated LLOQ concentration for each. All assays demonstrate acceptable CV at the LLOQ (i.e. 
≤20 %). Assay A is appropriate for the task, and would provide quantitative results for all but the 
pre-dose time point. Assay C is clearly not suitable for this study, since the designated LLOQ is 
too high for the concentrations achieved. For assay C, the majority of data points are BLQ and 
therefore cannot be reported numerically. However, since the CV of the assay is low at the 
designated LLOQ concentration, a re-validation of the same assay using a lower calibration range 
(inclusive of a lower LLOQ calibrator) might suffice to allow re-analysis of the study samples, 
and provide more usable numeric data. 
***Figure 1 goes here.*** 
Of particular interest are the results produced using assay B. Technically, enough data points are 
available to formulate a PK model, but a number of data points are below the LLOQ and would 
therefore be reported as BLQ. These BLQ data points may be very useful in clarifying the 
clearance of the drug by improving the PK model [1]. These BLQ data can be used in the 
estimation if concentrations are reported numerically as shown in a previously published study 
where actual BLQ data were used [1]. Keizer et al. [1] used an indisulam data set with uncensored 
concentrations BLQ, excluding concentrations below LOD to compare different BLQ data 
handling approaches.  
Current Status of Regulations and Bioanalytical Method Validation Guidelines 
Missing BLQ values could be viewed as the consequence of an historical lack of communication 
between clinicians, pharmacometricians and bioanalytical chemists and missing information about 
the expected concentration range. During the assay development, the LLOQ is chosen for assay 
validation. Assay validation will ensure the precision limits for the method LLOQ. Whilst there 
are a number of validation guidelines available, we will be focusing herein on the guidelines 
deemed most relevant for bioanalytical laboratories at the time of writing [7]. In Europe this is 
currently the European Medicines Agency (EMA)  guideline from 2011[3]. From the United States 
of America the Food and Drug Administration’s (FDA) ‘Guideline on bioanalytical method 
validation’, updated in 2013 [4] is reviewed. From Brazil, the Brazilian Health Regulatory Agency 
(ANVISA) validation guideline dates from 2012 [5]. ANVISA and EMA, as well as others, are 
mostly created in connection with, or on the basis of the FDA guideline, but extend the 
requirements in newer iterations [7]. China is preparing their own guideline (CFDA), a draft of 
which was issued in 2011. However, the finalised version has yet to be translated into English [9]. 
In Canada, the Health Canada Guidance for Industry Conduct and Analysis of Comparative 
Bioavailability Studies (2012) stipulates that EMA guidelines must be followed [10]. All three 
guidelines (FDA, EMA and ANVISA), as well as guidelines issued by Japan in [6], define the 
LLOQ as the lowest concentration of analyte which can be reliably quantified. Whilst the wording 
differs in each guideline document, the method for determining the LLOQ and the acceptance 
criteria do not. In all guidelines, LLOQ determination requires analysis of at least five samples at 
the LLOQ concentration, with (i) accuracy 80-120 % of the nominal concentration, (ii) precision 
lower than or equal to 20%, and (iii) a signal which is at least five times larger than that of a matrix 
blank response (noise) [6,7]. The limit of detection (LoD) is defined in the FDA draft guideline as 
the lowest concentration that can be reliably differentiated from blank samples [4]. The 
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use (ICH) has started work on a bioanalytical method validation guideline in October 
2016, with Step 4 (adoption of ICH harmonised guideline) planned for June 2019 [11]. Currently 
ICH has a general guideline “Validation of Analytical Procedures: Text and Methodology” Q2(R1) 
[11], which provides three options on how to determine LoD and LLOQ. However, only one of 
these options uses a mathematical formula for calculation (using standard deviation of the response 
and the slope of the calibration curve). The other two options use the signal-to-noise ratio value, 
and ‘visual evaluation’, respectively [11].  
In the GLP regulatory environment, the release of BLQ data is not justified by the laboratory as 
the reliability of this data is not covered by the method validation experiments [8]. 
Current Status of Bioanalytical Methods 
Commonly used chromatographic methods (liquid chromatographic (LC) and gas 
chromatographic (GC) with different detectors and also liquid chromatography-tandem mass 
spectrometry (LC-MS/MS)) use linear calibration curves for the quantification of analytes in 
samples, with confinements for accuracy and precision throughout the whole range. Even if the 
permitted accuracy (% nominal concentration) at the LLOQ is 80-120 %, and the permitted 
precision is less than or equal to 20 %, the measured precision for the designated LLOQ 
concentration can differ significantly between methods. For some validated bioanalytical methods, 
precision at the designated LLOQ concentration can be well below 5 %, whilst for other methods 
the precision may be much closer to the 20 % limit of acceptance (Figure 2). In the current 
regulatory environment, BLQ data should not be released by the analytical laboratory for PK 
modelling because these data are deemed unreliable [8]. In practice, depending on the performance 
of the assay, some of these BLQ data may in fact be at concentrations which, if tested during 
validation, would be within the requisite 20 % precision limits. It is the lack of supporting data 
which is critical in the release of these data.  
It can safely be assumed that the variance of the data increases sharply at concentrations below the 
LLOQ concentration. This can be demonstrated simply by plotting the assay precision against the 
nominal concentrations of calibrators (Figure 2). Following current method validation guidelines, 
no precision data are collected at concentrations below the designated LLOQ. Therefore, the exact 
concentration at which the precision exceeds the 20 % limit, and indeed how far below the 
designated LLOQ that concentration is, are both unknown quantities. With a method that displays 
a precision of 5 % at the LLOQ concentration, the precision at concentrations far below the LLOQ 
might very well be fit for purpose (assay C in Figure 2), but this information is simply not available 
without additional validation using a lower calibration range (i.e. with a re-assigned LLOQ 
calibrator). For methods where the precision at the LLOQ is already approaching 20 %, one may 
expect the actual concentration at which the 20 % limit is exceeded to be just below the designated 
LLOQ (assay A in Figure 2), but again this cannot be guaranteed or proven without additional 
validation work. Potentially, if bioanalytical laboratories could evaluate the accuracy and precision 
of BLQ data using pre-defined guidelines, recognised by the regulators, and ensure that PK 
modelling takes this analytical variability into account, BLQ data could be released for use in PK 
analyses, which could therefore improve our pharmacological understanding.  
***Figure 2 goes here.*** 
BLQ Data Treatment 
If BLQ data are censored one has to resort to statistical treatment [12]. Before Beal suggested 
different options to include samples BLQ into the modelling in 2001 [12], this data was merely 
discarded for non-compartmental analysis. Frequently the drug concentration decreases to BLQ in 
the case of the late time points in PK studies[13–17] or when the administered dose is very small 
[18–22]. BLQ data may also result from inter-individual variability that can influence drug 
absorption, excretion or degradation [23–26]. Occasionally, the majority of samples analysed 
within a PK study series are not quantifiable, for example due to a different administration 
procedure (e.g. subcutaneous) [27], rapid degradation of the parent drug [28] or usage of ‘an 
inadequate analytical method’ [29]. Sometimes it is even desired to push the analyte’s level BLQ 
with medication [21,30].  
For methods to manage BLQ data points, when they present a relatively small fraction of the total 
data, different procedures have been proposed, such as exclusion, partial exclusion, or substitution 
(e.g. with half the LLOQ, the LLOQ, or zero) [For references please see Table 1]. A comparisons 
of the most prominent options can be found here [1,12,31–35]. A brief overview of the different 
approaches used to treat BLQ data is provided in Table 1. 
***Table 1 goes here.*** 
Table 1: Summary of methods used to treat censored BLQ data. Method numbering system 
according to Beal, 2001 [12] where appropriate. 
BLQ data treatment option 
Method 
number 
Example study references 
Discard all BLQ data and model with remaining 
data 
M1 
[1,12,31–76] 
Discard BLQ data and estimate the likelihood of 
the remaining values to be greater than the 
LLOQ 
M2 
[12,31,77–79] 
Keep BLQ observations in the model and 
estimate the likelihood of those values being 
below LLOQ 
M3 
[1,12,31,33,34,39,48,52,53,55
–57,59,60,63,69,71–73,77–
185] 
Keep BLQ observations in the model and 
estimate the likelihood of those values being 
between 0 and LLOQ 
M4 
[12,35,116,180,186,187] 
All BLQ data are substituted with LLOQ/2 M5 
[12,24,30–
33,35,55,62,133,153,188–224]  
BLQ data are substituted with LLOQ/2, however 
subsequent, consecutive BLQ observations from 
the same subject are discarded 
M6 
[1,12,34,35,59,63,117,225–
243]  
All BLQ data are substituted with 0 M7 
[12,31,33,207,244] 
All BLQ data are substituted with LLOQ  
[245,246] 
Using data between LoD and LLOQ  [1,32,41,247–249] 
A comparison of several approaches for treating BLQ data points was conducted by Xu et al. [76]. 
They found that if the dataset contains a low percentage (≤10%) of BLQ data, then discarding 
these data is a valid option and does not increase the bias of the study [76]. Substituting BLQ 
values with 0 was found to be worse than substituting with half the value of LLOQ, since 
substitution with 0 introduced bias to the assessment [12].  
The likelihood-based methods – discarding BLQ data, but maximizing the likelihood of the 
remaining data being above LLOQ [12,34] – were found to work even better. Simulation of 
datasets is an option offered by the NONMEM® program [250–253]. Overall caution is advised, 
when using BLQ data due to the large variability of these data [2].  
It has been recommended by pharmacometricians that bioanalytical laboratories should release the 
BLQ data if the values are above the LoD [1] or the ‘lower limit of an assay’s ability to distinguish 
a concentration from zero’ [254]. Moreover, recently it has been demonstrated that uncensored 
BLQ data may be useful, even for the studies where <10 % of data are BLQ [1]. By comparing the 
M3 and M6 approaches (Table 1) for treating censored data and actual BLQ data, inclusion of 
uncensored BLQ data gave less bias and more precise parameter estimates [1]. 
A critically important piece of information that is currently missing from a standard bioanalytical 
method validation is the LoD. Whilst it is defined by the regulatory and guidance documents 
[4,255–260] it is not yet required to establish it experimentally in bioanalysis [4,7]. Furthermore, 
this parameter is not easily determined experimentally. There are a number of possible ways to 
determine the LoD, and these result in concentrations which may differ up to ten-fold [261,262].  
 
Bridging the Divide 
If possible, those assays used to analyse study samples which result in critical amounts of BLQ 
data should be re-designed and re-validated as a rule. Thereafter, the samples should be re-analysed 
in order to provide adequately reliable PK data (Figure 3). Resources to be considered and 
discussed between the analyst and the pharmacometricians are: (i) the sample amount left, (ii) the 
stability of the analyte in question,  (iii) the  funds necessary to re-validate the assay. 
If assay re-design is not possible, BLQ data precision should be evaluated. The following issues 
emerge when calculating values for BLQ data. Firstly, as a rule, BLQ data are outside the 
calibration range. Thus, aside from the precision considerations already discussed, calculating 
concentrations outside the calibration range from the calibration curve involves extrapolation 
assuming linearity. In reality, this might not hold true and the signal might behave in a non-linear 
fashion. 
For the purpose of PK modelling, it would be useful to evaluate the precision for BLQ data during 
method validation, although current guidelines do not require these experiments to be carried out. 
The LLOQ is the lowest concentration at which the precision is measured. Below this 
concentration, variability likely becomes unacceptable for the specific sample. In the case of PK 
modelling, however, especially if there are a number of data points, the precision requirements can 
be less stringent. Thus, data that are BLQ from the point of view of determining analyte 
concentration in a specific sample, might still be usable and reliably informative in model 
development [1].  
***Figure 3 goes here.*** 
Releasing results for extrapolated concentrations outside the validated calibration range of an assay 
is not justifiable from the point of view of the analytical chemist. One possible approach to 
overcome this, would be to include an additional experiment either during, or following, method 
validation to establish precision and accuracy at a concentration BLQ, and then report any BLQ 
data with the estimated CV (Figure 3). Using this approach, BLQ data are clearly labelled as 
‘outside the validated range of the assay’ and the decision whether and how to incorporate these 
data into a PK model can be taken by the data analyst (PK modeller/pharmacometrician).  
This suggestion involves amending current bioanalytical method validation protocols, to include 
(i) calculating the assay LoD and then (ii) experimentally measuring the accuracy and precision of 
the assay at the LoD concentration. For the former, the authors would strongly discourage the use 
of signal-to-noise calculation algorithms [261,262]. Results obtained using such approaches are 
software-dependent, and can be significantly influenced by data processing, e.g. chromatographic 
smoothing [263]. 
Statistically, the LoD of a method depends on the sensitivity (as defined by the slope of the 
calibration graph), and variability at concentrations approaching the LoD and 0. To calculate the 
LoD using data already acquired during the requisite method validation, the following equation 
provides a simple, and useful estimate: 
𝐿𝑜𝐷 = 3.3 ∗
𝑆𝐷(𝐿𝐿𝑜𝑄)
𝑆
 
(i)
 
Where SD(LLOQ) is the standard deviation of the analyte response (or the response ratio to an 
internal standard) of replicate measurements of analyte in the sample matrix prepared at the LLOQ 
concentration, and S is the slope of a line drawn between the origin and the mean response of the 
replicates at the nominal LLOQ concentration (Figure 4). By using this SD(LLOQ) value, variance 
is assumed to be equal for BLQ concentrations, which leads to conservative (higher) LoD 
concentrations. Moreover, using this equation assumes linearity between LoD and LLOQ, and that 
the curve passes through the origin (i.e. blank samples give an intensity response that is not 
significantly different from 0). This equation is based on commonly used approaches of estimating 
LoD. Detailed discussion about these LoD estimation approaches can be found in the following 
reference [261,262]. 
***Figure 4 goes here.**** 
Alternative LoD estimation approaches are available [261,262] which make fewer assumptions 
than the approach described above, and therefore provide more statistically accurate estimates of 
the SD and slope at LoD concentrations. However, these approaches require additional 
measurements to be undertaken (e.g. preparation and replicate analysis of further quality control 
samples at additional concentrations), which are not included in the existing method validation 
guidelines.  
The magnitude of the influence of the assumptions (made when using the approach suggested 
above) depends on the analytical method (its linearity and scedasticity) and the distance between 
LLOQ from LoD. Whether this approach is suitable or whether the assumptions made are 
unacceptably large should, in our opinion, form a topic of further debate.  
The approach proposed is only useful for experimentally determining the precision at a 
concentration BLQ, called here calculated LoD. A blank matrix should be fortified at this LoD 
concentration and the between-day variability should be estimated using 5 samples in 3 batches 
each. Using this approach may even result in a CV below the 20% limit for LLOQ. Yet, the 
estimated concentration at that level may potentially be very different from the nominal 
concentration in the fortified sample. The potential difference is principally a result of the 
extrapolation of the calibration curve (Figure 4). Therefore, the reported assay LoD should be the 
nominal/calculated concentration and the precision must be calculated using that calculated LoD. 
The approach proposed above is not suitable for standard addition methods for endogenous 
compounds analysis.  
Any concentration below the calculated LoD concentration should be reported as ‘below LoD of 
xx’ or ‘not detected’ which means that this analytical method cannot differentiate the concentration 
of this sample from a blank sample. For results between the measured LoD concentration and the 
LLOQ concentration, results could be reported as a numeric concentration with the caveats that (i) 
the concentration is below the validated LLOQ and (ii) the precision of these values was measured 
experimentally as XX % (CV). 
Future perspective 
There will always be studies that observe data BLQ. The goal is to minimise the impact of 
occurrence of BLQ data, thus maximising the utility of the whole dataset. For achieving this, 
pharmacometric modellers and bioanalytical scientists need to work together when designing study 
protocols. This will help to ensure that concentration ranges in PK/PD studies are, wherever 
possible, correctly anticipated in advance, and that assay sensitivity is calibrated accordingly.  
If enough sample is left and the stability of the compound is acceptable, a new method validation 
with lower LLOQ is a viable option. Even a small fraction of BLQ data can be helpful in the 
estimation of PK and PD parameters, yet, when the imprecision of BLQ outweighs the benefits of 
using the data, new data needs to be generated to assure correct interpretation from the study 
concerned. 
Where assay sensitivity is identified as being potentially problematic, in that a large proportion of 
points are under a standard study design are expected to be BLQ, it is incumbent on the 
pharmacometrician to design an alternative sampling schedule that minimises the proportion of 
BLQ data.   
BLQ data cannot be released and used for PK analysis without evaluation of the precision. In case 
the suggested approach of determination of variance at the LoD is used, data analysts have to make 
the final decision about the suitability of these data for PK analytical purposes and should 
incorporate the between-day variance into their PK model specification.  
Incorporation of a consistent LoD definition, independent of the signal to noise ratio, into the 
bioanalytical method validation guidelines is encouraged and welcomed. In contrast to the 
arbitrarily assigned 20% CV accuracy and precision for the LLOQ, the LoD could become the 
solid mark for analytical performance. A set definition of variance limits for the LoD however, 
might not be a good way forward, as it applies very tight restrictions for successful method 
validations.  
With a clear, but not too restrictive, approach for determining the LoD in place, releasing BLQ 
data can become a standard procedure in PK studies.  
Certainly, the BLQ topic needs further exploration using data simulations and actual real data from 
different assays to establish the most suitable approach for incorporating BLQ data variability in 
PK analyses.  
The following recommendations can therefore be made: 
For bioanalytical laboratories: 
 If proportion of BLQ data is large, and if possible, re-design and re-validate the assay, 
lowering LLOQ  
 If assay reanalysis of the study samples is not possible, estimate assay LoD using the 
proposed approach  
 After evaluation of the between-day precision of the LoD, release the BLQ data with 
experimentally acquired CV  
For regulators: 
 Incorporate the LoD into validation guidelines 
 Accept and trust laboratory data if the set tests are conducted by allowing the data release 
and shift the decision-making about the usability of these data to data analysts 
For pharmacometricians and clinicians:  
 Provide enough information about the study design and expected analyte concentrations to 
support method accuracy, precision and reliability of the results that will be obtained.  
 Use mathematical models to incorporate the variability and measurement uncertainty 
throughout PK modelling – reflecting larger variance at lower concentrations. This does 
not have to entail estimation per sample, as estimates can be calculated from the actual 
validation data, and/or quality control samples. 
 PK/PD study sampling time points derived using optimal design or simulation-estimation 
should take into account the expected LOQ values. 
  
Executive summary 
Below Limit of Quantitation data 
 BLQ data is an issue for many PK/PD analyses, particularly when studies are poorly-
designed  
 Historically the handling and release of BLQ data have been hampered by a lack of 
communication between bioanalytical chemists, clinicians and pharmacometricians  
 BLQ data is unvalidated and unreliable for making individual decisions on individual 
samples  
Regulations and Bioanalytical Method Validation Guidelines 
 Method validation regulations should investigate the possibility of incorporating LoD and 
BLQ variability estimation into the procedure. 
Bioanalytical Assays 
 Assays are designed based on the information provided. Assay precision at LLOQ level 
can be well below 5% or close to 20%.  
 Bioanalytical assays are not required to measure LoD and are not currently validated BLQ.  
 If extra validation experiments are not done, no information about the precision of BLQ 
data is available. 
BLQ Data Treatment 
 When comparing multiple ways of treating censored BLQ data, using the actual BLQ 
values is known to be the most accurate. 
 PK and PD analysis should account for the variance of the analytical method across the 
calibration range and also below this range. 
Bridging the Divide 
 The LLOQ is the lowest concentration at which accuracy and precision are measured. 
Below this concentration, variability likely becomes unacceptable for the specific sample. 
In the case of PK modelling, however, especially if there are a number of data points, the 
precision requirements can be less stringent. 
 LoD estimation and evaluation of its precision is proposed and encouraged in order to use 
this information to facilitate appropriate handling of the BLQ data. 
 It would then be possible for BLQ to be released with evaluated precision. 
 The decision regarding whether and how to incorporate the BLQ data into a PK(/PD) 
model, and the justification for such decisions, should ultimately be the responsibility of 
the PK/PD analyst and not the analytical chemist. 
Figure captions: 
Figure 1. Pharmacokinetic model measured with 3 different analytical methods, each having a 
different LLoQ and different CV. 
 
Figure 2. Variability of data measured at different concentrations using 3 different analytical 
methods. Distinct assays display different CV-increases below LLoQ. 
 
Figure 3. Proposed workflow to evaluate the options for a study with BLQ data. 
 
Figure 4. Estimation of LoD from assay validation data and the impact of linear extrapolation of 
BLQ data from two batch calibration curves. 
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